GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (NAS:RSLS) » Definitions » Median PS Value

RSLS (Reshape Lifesciences) Median PS Value : $0.00 (As of Apr. 02, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Reshape Lifesciences's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $18.738. Reshape Lifesciences's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2025-04-02), Reshape Lifesciences's share price is $0.45. Reshape Lifesciences's Median PS Value is $0.00. Therefore, Reshape Lifesciences's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Reshape Lifesciences's Median PS Value or its related term are showing as below:

RSLS's Price-to-Median-PS-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.74
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Reshape Lifesciences Median PS Value Historical Data

The historical data trend for Reshape Lifesciences's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Median PS Value Chart

Reshape Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Reshape Lifesciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Reshape Lifesciences's Median PS Value

For the Medical Devices subindustry, Reshape Lifesciences's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reshape Lifesciences's Price-to-Median-PS-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's Price-to-Median-PS-Value falls into.


;
;

Reshape Lifesciences Median PS Value Calculation

Reshape Lifesciences's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=18.738*0
=0.00

10-Year Median PS Ratio is 0.
Reshape Lifesciences's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.738.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reshape Lifesciences  (NAS:RSLS) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Reshape Lifesciences's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.45/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reshape Lifesciences Median PS Value Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Reshape Lifesciences Business Description

Traded in Other Exchanges
N/A
Address
18 Technology Dr., Suite 110, Irvine, CA, USA, 92618
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
Executives
Thomas Stankovich officer: Chief Financial Officer 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Paul F. Hickey director, officer: President and CEO 2800 PATTON ROAD, ST. PAUL MN 55113
Barton P. Bandy director 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Mcdougal Lori Courtney director 2800 PATTON ROAD, ST. PAUL MN 55113
Arda Phd Minocherhomjee director C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606
Dan W Gladney director 2800 PATTON ROAD, ST. PAUL MN 55113
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Gary Blackford director 7700 FRANCE AVENUE SOUTH, EDINA MN 55435
Robert J Macdonald officer: Chief Retail Officer C/O OBALON THERAPEUTICS INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Daina Schmidt officer: Vice President of Marketing C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Gilbert H Kliman 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Arnold L Oronsky 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Khaled Nasr 10 percent owner 467 FIRST STREET, SUITE 201, LOS ALTOS X1 94022
Interwest Partners X Lp 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022